Real-world evidence of the safety and efficacy profile of suvorexant in elderly patients with insomnia: a sub-analysis of the post-marketing drug-use results survey in Japan

<b>Objective:</b> Global Phase III trials of suvorexant showed no obvious differences in the safety and efficacy profile of suvorexant between elderly and non-elderly patients. However, the clinical profile of suvorexant in elderly patients with comorbidities in a real-world setting was not evaluated. To further understand the safety and efficacy profile of suvorexant in elderly patients with insomnia in a daily clinical practice setting, we conducted a sub-group analysis of the post-marketing drug-use results survey. <b>Methods:</b> Patients with insomnia who were treated with suvorexant for the first time were divided into three groups: group-1 (&lt;65 years, <i>N</i> = 1490), group-2 (≥65 years and &lt;75 years, <i>N</i> = 730), and group-3 (≥75 years, <i>N</i> = 1028). <b>Results:</b> The incidence of overall adverse drug reactions (ADRs) were 11.28% (<i>N</i> = 168), 8.63% (<i>N</i> = 63), and 8.17% (<i>N</i> = 84) in group-1, -2, and -3, respectively. The ADRs most commonly observed in this survey were somnolence, insomnia, and dizziness, with no new safety concerns or differences in safety issues found. The numbers of patients in group-1, -2, and -3 who visited internal medicine departments were: 690 patients (46.3%), 521 patients (71.4%), and 793 patients (77.1%), respectively. The percentage of patients who were deemed to have “improved”, based on the patient’s self-assessment and their physician’s assessment, was 70–75% of patients in all groups. <b>Conclusion:</b> These results reveal the safety and efficacy profile of suvorexant in elderly patients who often have various and multiple comorbidities and were treated in a daily clinical practice setting.